201920182017201620152014 November 05, 2018 Summary ToggleSpero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial October 11, 2018 Summary ToggleSpero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206 September 27, 2018 Summary ToggleSpero Announces Positive SPR994 Phase 1 SAD/MAD Final Results September 25, 2018 Summary ToggleSpero Therapeutics Announces Presentations at IDWeek 2018 September 19, 2018 Summary ToggleSpero Therapeutics to Present at the Cantor Global Healthcare Conference in October August 28, 2018 Summary ToggleSpero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference August 14, 2018 Summary ToggleSpero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors August 09, 2018 Summary ToggleSpero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview July 16, 2018 Summary ToggleSpero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development July 12, 2018 Summary ToggleSpero Therapeutics Announces Pricing of Securities Offering Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
